Frequency Therapeutics, Inc.

As of March 18, 2025, Frequency Therapeutics, Inc. is considered a risky investment due to its negative financial metrics, including a P/E ratio and troubling returns, and has underperformed significantly compared to the S&P 500.

As of June 6, 2025, the market trend is mildly bearish, indicated by mixed signals from the MACD, moving averages, Bollinger Bands, and KST, suggesting cautious optimism amid some positive momentum.

As of March 2022, the management team of Frequency Therapeutics, Inc. includes Lead Independent Chairman Marc Cohen, CEO David Lucchino, and several Independent Directors: Timothy Barberich, Cynthia Feldmann, Michael Huang, Robert Langer, and Joel Marcus. They are responsible for guiding the company's strategic direction and operations.

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small molecule drugs to regenerate healthy tissue. As of March 2025, it reported net sales of $3 million and a net loss of $23 million, with a market cap of $118.04 million.

As of Jun 18, Frequency Therapeutics, Inc. has a market capitalization of 118.04 million and reported net sales of 4.82 million with a net profit of -87.42 million over the latest four quarters.